Record Display for the EPA National Library Catalog

RECORD NUMBER: 334 OF 922

OLS Field Name OLS Field Data
Main Title Enforceability Aspects for RACT (Reasonably Available Control Technology) for the Chemical Synthesis Pharmaceutical Industry.
Author Briggs, T. ; Harvey, C. ; McClure, J. ; Pollard-Cavalli, R. ;
CORP Author PEDCo-Environmental, Inc., Cincinnati, OH.;Environmental Protection Agency, Washington, DC. Div. of Stationary Source Enforcement.
Year Published 1981
Report Number EPA-68-01-4147; EPA-340/1-80-016;
Stock Number PB84-189380
Additional Subjects Drug industry ; Synthesis(Chemistry) ; Law enforcement ; Air pollution control ; Manufacturing ; Organic compounds ; Forecasting ; Surveys ; Industrial wastes ; Process charting ; Design criteria ; Reviews ; Regulations ; Mathematical models ; Recommendations ; Reasonably available control technology ; Volatile organic compounds ; Air pollution abatement ; Air quality ; Clean Air Act Amendments of 1977
Internet Access
Description Access URL
http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=50000JSO.PDF
Holdings
Library Call Number Additional Info Location Last
Modified
Checkout
Status
NTIS  PB84-189380 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. NTIS 06/23/1988
Collation 93p
Abstract
Reasonably available control technology (RACT) requirements apply to pharmaceutical manufacturing plants using synthesis processes that emit more than 15 pounds per day of volatile organic compounds (VOC) located in photochemical oxidant nonattainment areas. There are 140 operating pharmaceutical plants that use chemical synthesis processes in the 10 U.S. Environmental Protection Agency regions; 116 of these are located in nonattainment areas. A current survey of the operating synthetic pharmaceutical manufacturing plants is necessary for the enforcement of RACT and for long-range planning of EPA, regional, and local programs and resources. This report provides an inventory of the operating synthetic pharmaceutical manufacturing plants, an industry process description, a review of the RACT requirements, and an evaluation of the model regulations to identify enforceability problems.